Bioxytran (BIXT) Non-Current Debt (2010 - 2024)
Bioxytran (BIXT) posted Non-Current Debt of $948071.0 for Q1 2024, down 55.36% sequentially from $2.1 million in Q4 2023, and down 59.04% YoY from $2.3 million in Q2 2023.
Bioxytran (BIXT) Non-Current Debt (2010 - 2024) Analysis & Trends
Bioxytran has reported Non-Current Debt for 6 years, with the latest figure at $948071.0 in Q1 2024.
- Quarterly Non-Current Debt fell 59.04% year-over-year to $948071.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $948071.0 (down 59.04% YoY) and the FY2023 annual result came in at $2.1 million, down 7.65% from the prior year.
- Non-Current Debt declined to $948071.0 in Q1 2024 per BIXT's latest filing, from $2.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $3.8 million in Q2 2022 and troughed at $948071.0 in Q1 2024.
- A 4-year average of $2.2 million and a median of $2.2 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt rose 2.17% in 2022, then slumped 59.04% in 2024.
- Over 4 years, Non-Current Debt stood at $2.3 million in 2021, then rose by 2.17% to $2.3 million in 2022, then declined by 7.65% to $2.1 million in 2023, then tumbled by 55.36% to $948071.0 in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $948071.0, $2.1 million, and $1.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 948,071.00 |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Dec 31, 2021 | 2.25 Mn |
| Dec 31, 2013 | 80,000.00 |
| Dec 31, 2010 | 2,132.00 |